Can a smartwatch replace the clinic walk test for lung disease patients?
NCT ID NCT03893500
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial tests whether an Apple Watch paired with a special app can accurately measure how far people with pulmonary arterial hypertension (PAH) can walk in six minutes — both in the clinic and at home. Researchers want to see if daily home-based walk tests can detect changes in a patient's condition earlier than standard in-clinic tests. The study involves 63 adults with PAH who will use the watch and app daily for 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Apple Watch with Walk.Talk.Track. app for home-based six-minute walk tests
- What this could lead to
- If accurate, this approach could let doctors monitor PAH patients remotely, catching changes earlier and reducing clinic visits.
- What could go wrong
- The trial is small and early, focused on accuracy rather than treatment effects. The technology may not work reliably for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
63 people
The number who actually took part.
- Started
-
Jul 2020
- Finished
-
Jun 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of WHO Group I Pulmonary Arterial Hypertension (PAH) (Idiopathic (I)PAH, Heritable PAH (including Hereditary Hemorrhagic Telangiectasia), Associated (A)PAH (including collagen vascular disorders, drugs+toxins exposure, congenital heart disease, and portopulmonary disease). * Do not meet exclusion criteria Exclusion Criteria: * Pulmonary Hypertension due to left heart disease (PH-LHD, WHO group 2), Pulmonary hypertension due to chronic lung disease (PH-CLD, WHO group 3), Chronic thrombo-embolic pulmonary hypertension (CTEPH, WHO group 4), pulmonary hypertension with unclear and/or multi-factorial mechanisms (WHO goup 5) * Inability to perform a 6 minute walk test (6MWT)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- A 10-Question survey could give brazilian pulmonary hypertension patients a voice in their care
- Experimental blood pressure drug put to the test in healthy volunteers
- Can a new drug keep pulmonary arterial hypertension in check over the long haul?
- Could light leg workouts revive Oxygen-Starved muscles in PAH?
- Texting therapy: could a simple phone message boost exercise and quality of life in a rare lung disease?